AbbVie's Post-Humira Strategy Is Paying Off For Investors

(12min)

Summary

  • AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors.
  • The company has successfully transitioned from Humira, with Rinvoq and Skyrizi driving impressive revenue growth and offsetting patent expirations.
  • AbbVie's robust pipeline and strategic acquisitions position it for continued growth, supporting ongoing dividend increases and shareholder returns.
  • Despite missing earlier buying opportunities, I now rate AbbVie a buy, due to its resilient business model and reliable dividend outlook.
AbbVie

hapabapa

Investing Thesis

As an income-oriented investor, I am always on the lookout for high-yielding stocks with strong track records of dividend growth and promising trajectories for continued growth moving forward. When I first began investing, I made a few novice mistakes, the most notable

This article was written by

The Low-Budget Dividend Investor is your prototypical Generation X-er: an over-educated, under-funded middle-aged guy looking for ways to increase his income in a difficult economic environment. He favors the conservative, income-generating strategies more frequently associated with those portfolios belonging to people twenty or thirty years his elder while still acknowledging the wisdom of the growth investors ten years his junior.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ABBV

Related Stocks

SymbolLast Price% Chg
ABBV
--
ABBV:CA
--